Annexin A1 in plasma from patients with bronchial asthma: its association with lung function

Abstract

BackgroundAnnexin-A1 (ANXA1) is a glucocorticoid-induced protein with multiple actions in the regulation of inflammatory cell activation. The anti-inflammatory protein ANXA1 and its N-formyl peptide receptor 2 (FPR2) have protective effects on organ fibrosis. However, the exact role of ANXA1 in asthma remains to be determined. The aim of this study was to identify the role of ANXA1 in bronchial asthma.MethodsIn mice sensitized and challenged with ovalbumin (OVA-OVA mice) and mice sensitized with saline and challenged with air (control mice), we investigated the potential links between ANXA1 levels and bronchial asthma using ELISA, immunoblotting, and immunohistochemical staining. Moreover, we also determined ANXA1 levels in blood from 50 asthmatic patients (stable and exacerbated states).ResultsANXA1 protein levels in lung tissue and bronchoalveolar lavage fluid were significantly higher in OVA-OVA mice compared with control mice. FPR2 protein levels in lung tissue were significantly higher in OVA-OVA mice compared with control mice. Plasma ANXA1 levels were increased in asthmatic patients compared with healthy controls. Plasma ANXA1 levels were significantly lower in exacerbated patients compared with stable patients with bronchial asthma (p < 0.05). The plasma ANXA1 levels in controlled asthmatic patients were correlated with forced expiratory volume in 1 s (FEV1) (r = − 0.191, p = 0.033) and FEV1/forced vital capacity (FVC) (r = −0.202, p = 0.024).ConclusionThese results suggest that ANXA1 may be a potential marker and therapeutic target for asthma.

The first report of Methicillin-resistant Staphylococcus aureus (MRSA) in cystic fibrosis (CF) patients in Saudi Arabia

“…Several proposed eradication protocols have been reported thus far ( Table 1 ) [ [12] , [13] , [14] , [15] , [16] ]. Lo, D. et al.…”

Successful treatment with mepolizumab for allergic bronchopulmonary mycosis complicated with bilateral septic arthritis of the knee joints caused by Methicillin-resistant Staphylococcus aureus

“…Therefore, we expected mepolizumab to be efficacious for treatment of ABPM. Several cases of ABPM treated with mepolizumab have been reported so far [ [14] , [15] , [16] , [17] , [18] , [19] , [20] ]. All were controlled, and none of these patients experienced adverse events with mepolizumab.…”

Mimetic peptide AC2-26 of annexin A1 as a potential therapeutic agent to treat COPD

“…Similar results were found by our research group in a model of endotoxin induced uveitis [27], in which the antiinflammatory role of Ac2-26 was abrogated by the nonselective FPR antagonist, Boc2. The expression of AnxA1 and its relation to FPR receptors were also investigated in the respiratory tract [31,54,55]. AnxA1 and FPR2 levels in lung tissue and BAL were significantly higher in mice sensitized and challenged with ovalbumin compared with control animals [55].…”

“…The expression of AnxA1 and its relation to FPR receptors were also investigated in the respiratory tract [31,54,55]. AnxA1 and FPR2 levels in lung tissue and BAL were significantly higher in mice sensitized and challenged with ovalbumin compared with control animals [55]. Increased lung edema, neutrophil infiltration, inflammatory cytokine release, oxidative stress, apoptosis, translocation of nuclear factor (NF)-κB and tissue damage were attenuated by Ac2-26 and FPR activation in acute lung injury induced by Ischemia-Reperfusion in rats, but the protective effect of Ac2-26 administration was reduced by Boc2 [54].…”